Mutations in an Aquaglyceroporin as a Proven Marker of Antimony Clinical Resistance in the Parasite Leishmania donovani
JE Potvin, P Leprohon, M Queffeulou… - Clinical Infectious …, 2021 - academic.oup.com
Background Antimonial drugs have long been the mainstay to treat visceral leishmaniasis.
Their use has been discontinued in the Indian subcontinent because of drug resistance, but …
Their use has been discontinued in the Indian subcontinent because of drug resistance, but …
Antimony resistance and gene expression in Leishmania: spotlight on molecular and proteomic aspects
RK Madusanka, ND Karunaweera, H Silva… - Parasitology, 2024 - cambridge.org
Leishmaniasis is a vector-borne parasitic disease caused by Leishmania parasites with a
spectrum of clinical manifestations, ranging from skin lesions to severe visceral …
spectrum of clinical manifestations, ranging from skin lesions to severe visceral …
[HTML][HTML] Leishmania spp. genetic factors associated with cutaneous leishmaniasis antimony pentavalent drug resistance: a systematic review
BACKGROUND Leishmaniasis is a neglected zoonosis caused by parasites of Leishmania
spp. The main drug used to treat cutaneous leishmaniasis (CL) is the antimoniate of …
spp. The main drug used to treat cutaneous leishmaniasis (CL) is the antimoniate of …
Antimony resistance in Leishmania (Viannia) braziliensis clinical isolates from atypical lesions associates with increased ARM56/ARM58 transcripts and reduced …
JN Rugani, CMF Gontijo, F Frézard… - Memórias do Instituto …, 2019 - SciELO Brasil
BACKGROUND In addition to the limited therapeutic arsenal and the side effects of
antileishmanial agents, drug resistance hinders disease control. In Brazil, Leishmania …
antileishmanial agents, drug resistance hinders disease control. In Brazil, Leishmania …
Molecular characteristic of treatment failure clinical isolates of Leishmania major
G Eslami, S Hatefi, V Ramezani, M Tohidfar… - PeerJ, 2021 - peerj.com
Background Leishmaniasis is a prevalent tropical disease caused by more than 20
Leishmania species (Protozoa, Kinetoplastida and Trypanosomatidae). Among different …
Leishmania species (Protozoa, Kinetoplastida and Trypanosomatidae). Among different …
[HTML][HTML] The mutation G133D on Leishmania guyanensis AQP1 is highly destabilizing as revealed by molecular modeling and hypo-osmotic shock assay
Abstract The Leishmania aquaglyceroporin 1 (AQP1) plays an important role in
osmoregulation and antimony (Sb) uptake, being determinant for resistance to antimony. We …
osmoregulation and antimony (Sb) uptake, being determinant for resistance to antimony. We …
Mitogen-Activated Protein Kinase and Aquaglyceroporin Gene Expression in Treatment Failure Leishmania major
R Somee, G Eslami, M Vakili - Acta Parasitologica, 2022 - Springer
Purpose Leishmaniasis comprises various clinical forms mainly including cutaneous, muco-
cutaneous, and visceral leishmaniasis; caused by Leishmania species. Antimoniate is the …
cutaneous, and visceral leishmaniasis; caused by Leishmania species. Antimoniate is the …
[PDF][PDF] Investigation of single nucleotide polymorphisms in MRPA and AQP-1 genes of Leishmania donovani as resistance markers in visceral leishmaniasis in Kenya.
Investigation of single nucleotide polymorphisms in MRPA and AQP-1 genes of Leishmania
donovani as resistance markers in viscera Page 1 AIMS Molecular Science, 8(2): 149–160 …
donovani as resistance markers in viscera Page 1 AIMS Molecular Science, 8(2): 149–160 …
Phylogenetic study of treatment failure clinical isolates of Leishmania major
S Hatefi, V Ramezani, M Tohidfar, G Eslami… - 2020 - researchsquare.com
Background: Molecular characteristics are necessary for designing programs for the control,
prevention, and treatment against cutaneous leishmaniasis. In the present study, treatment …
prevention, and treatment against cutaneous leishmaniasis. In the present study, treatment …